The Centre for Genomic Regulation (CRG) is an international biomedical research institute of excellence, created in December 2000. It is a non-profit foundation funded by the Catalan Government through the departments of Economy & Knowledge and Health, the Spanish Ministry of Economy and Competitiveness, 'la Caixa' Banking Foundation, and includes the participation of Pompeu Fabra University (UPF). The mission of the CRG is to discover and advance knowledge for the benefit of society, public health and economic prosperity. The CRG believes that the medicine of the future depends on the groundbreaking science of today. This requires an interdisciplinary scientific team focused on understanding the complexity of life from the genome and the cell up to an entire organism and its interaction with the environment, offering an integrated view of genetic diseases. The CRG's main goals are: a) to be a world-leading centre in biomedical science; b) to communicate and establish a bilateral dialogue with society; c) to provide advanced training for the next generation of scientists; and d) to transform new scientific knowledge into benefits for health and economic value for society.
44
Total Investments
36
Portfolio Companies
-
Exits
2
Industries
General Information
Industries
Biotechnology, Information Technology
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About CRG
Recent Investments (44)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Post-IPO Equity | •••••• | Feb 2024 | |
| Series C | •••••• | Jul 2022 | |
| Debt Financing | •••••• | May 2021 | |
| Debt Financing | •••••• | Aug 2020 | |
| Debt Financing | •••••• | Mar 2019 | |
|
|
Debt Financing | •••••• | Feb 2019 |
|
|
Venture Round - Mid | •••••• | Jan 2019 |
|
|
Private Equity Round | •••••• | Nov 2018 |
|
|
Series C | •••••• | Jul 2017 |
|
|
Post-IPO Debt | •••••• | Jul 2017 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.